secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001558370-24-004601
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path provides 2024 clinical update: AML, solid tumor trials advancing
-------------------------------------------------------------------------

- Phase 2 prexigebersen trial in AML targets FDA Fast Track for fragile patients; median survival 5-10 months.
- Phase 1/1b BP1001-A in solid tumors advanced to second dose level; Phase 1b with paclitaxel planned.
- Phase 1/1b BP1002 in relapsed/refractory AML enrolling at 40 mg/m2; no DLTs at 20 mg/m2.
- Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort (40 mg/m2) after no DLTs.
- Patent portfolio: 5 US and 53 foreign issued patents covering DNAbilize technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024004601/0001558370-24-004601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024004601/bpth-20240402x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-004601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer